NCT03051256 · Interventional trial
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Overall registry status Completed
Phase 2
Conditions Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Delaware Valley sites
- Hassman Research Institute · Berlin, NJ · Camden County
First posted
Registry updated
Added to the directory